Title: Microvessel Density among the Morphological Types of Multiple Myeloma
Authors: Dr Parvathy V, Dr Sheeja S, Dr Renu Thambi, Dr Sankar S
DOI: https://dx.doi.org/10.18535/jmscr/v8i2.167
Abstract
Background: Multiple myeloma is a malignant plasma cell dyscrasia which is characterised by bone marrow plasmacytosis. Multiple myeloma causes 1 % of all cancer deaths in western population.
Objectives
- To describe the various morphological types of myeloma in bone marrow examination and its kappa and lambda expression
- To assess the microvessel density using CD 34 in the bone marrow biopsy of patients with multiple myeloma
Methods
Study Design: Descriptive study
Study Population: Study sample includes all the cases of multiple myeloma received in the Department of Pathology during the study period.
Sample Size: 64
Sampling Procedure: Continuous sampling
Results: In our study, myeloma with plasma cell morphology constituted 57.82% and plasmablastic morphology constituted 42.18 %. A high microvessel density above the cut off value was seen in 28 cases (43.75 %) and a low MVD in 36 cases (56.25 %).In all the cases monoclonality was proved by kappa and lambda light chain restriction. In the present study, plasmablastic morphology was found to have a higher microvessel density compared to plasmacytic type. It was also suggested that a higher microvessel density was seen in cases with plasma cell percentage of more than 50 % and diffuse plasma cell infiltration in the bone marrow.
Conclusion: Statistically significant association was detected between microvessel density and the plasma cell morphology. Microvessel density was found to be higher with plasma cell morphology.
Keywords: Multiple myeloma; microvessel density (MVD); kappa and lambda.
References
- N, Kataria. S.P, S. Malik, N.Sharma and S. Kumar; Histopathological Spectrum of Central Nervous System Tumours in a tertiary care referral centre- A one year study. International Journal of Basic and Applied Medical Sciences. 2014;4(2):141-145.
- Nibhoria S, KaurTiwana K, Phutela R, Bajaj A, Chhabra S. Histopathological Spectrum of Central Nervous System Tmours: A single centre study of 100 cases. International Journal of Scientific Study, 2015;p 130- 134. 2015;3(6):130- 134.
- Louis D. WHO classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2016.
- A. Elsers and Noha. A. Aboulhagag; Expression of Ki-67, EGFR and its ligand in different grades of Meningiomas; AAMJ, 2012; p 34-56.
- Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. Journal of Cellular Physiology. 2000;182(3):311-322
- Drake R, Vogl W, Mitchell A, Gray H. Gray's anatomy for students. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
- Young B, O'Dowd G, Woodford P. Wheaters functional histology. 6th ed. Philadelphia: Reed Elsevier; 2014: 384-401
- Sengupta S, Banerjee U, Chatterjee S, Chatterjee U, Ghosh S, Ghosh A. A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group. Indian Journal of Medical and Paediatric Oncology. 2012;33(1):25.
- Aryal G. Histopathological pattern of central nervous system tumor: A three year retrospective study. Journal of Pathology of Nepal. 2011;1(1):22-25.
- Alomar S. Clinical manifestation of central nervous system tumor. Seminars in Diagnostic Pathology. 2010;27(2):97-104.
- Harnsberger H, Dillon W. Imaging Tumors of the Central Nervous System and Extracranial Head and Neck. CA: A Cancer Journal for Clinicians. 1987;37(4):225-238.
- Essig M, Anzalone N, Combs S, Dörfler A, Lee S, Picozzi P et al. MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice. American Journal of Neuroradiology. 2011;33(5):803-817.